Prevail Therapeutics Inc. - common stock (PRVL): Price and Financial Metrics
PRVL Price/Volume Stats
| Current price | $23.00 | 52-week high | $23.35 |
| Prev. close | $23.02 | 52-week low | $9.02 |
| Day low | $22.97 | Volume | 2,619,900 |
| Day high | $23.13 | Avg. volume | 955,800 |
| 50-day MA | $16.67 | Dividend yield | N/A |
| 200-day MA | $14.45 | Market Cap | 787.66M |
PRVL Stock Price Chart Interactive Chart >
Prevail Therapeutics Inc. - common stock (PRVL) Company Bio
Prevail Therapeutics, Inc. develops therapeutics for neurodegenerative diseases. The firm engages in the research and development of novel biologic gene therapies to treat Parkinson's disease and other neurodegenerative diseases. The company was founded by Asa Abeliovich on July 6, 2017 and is headquartered in New York, NY.
Latest PRVL News From Around the Web
Below are the latest news stories about Prevail Therapeutics Inc that investors may wish to consider to help them evaluate PRVL as an investment opportunity.
Lilly Completes Acquisition of Prevail TherapeuticsEli Lilly and Company (NYSE:LLY) today announced the successful completion of its acquisition of Prevail Therapeutics Inc. (NASDAQ: PRVL). The acquisition establishes a new modality for drug discovery and development at Lilly, extending Lilly's research efforts through the creation of a gene therapy program that will be anchored by Prevail's portfolio of clinical-stage and preclinical neuroscience assets. |
INVESTOR ALERT: Monteverde & Associates PC Is Actively Investigating the TransactionNEW YORK, NY / ACCESSWIRE / January 14, 2021 / Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018 and 2019 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating: * ZAGG, Inc. (NASDAQ:ZAGG) relating to its proposed acquisition by Evercel, Inc and its group. |
SHAREHOLDER ALERT: Halper Sadeh LLP Investigates BPFH, SPWH, PRVL, SNCA; Shareholders Are Encouraged to Contact the FirmNEW YORK, NY / ACCESSWIRE / January 13, 2021 / Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:Boston Private Financial Holdings, Inc. (NASDAQ:BPFH) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to SVB Financial Group. |
SHAREHOLDER ALERT: Monteverde & Associates Continues to Investigate the Following MergerNEW YORK, NY / ACCESSWIRE / January 12, 2021 /Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City, is investigating: * PNM Resources, Inc. (NYSE:PNM) relating to its proposed acquisition by Avangrid, Inc. |
INVESTIGATION ALERT: Halper Sadeh LLP Investigates BPFH, MDCA, MTSC, PRVL; Shareholders Are Encouraged to Contact the FirmNEW YORK, Jan. 12, 2021 (GLOBE NEWSWIRE) -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Boston Private Financial Holdings, Inc. (NASDAQ: BPFH) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to SVB Financial Group. Under the terms of the merger agreement, Boston Private shareholders will receive 0.0228 shares of SVB common stock and $2.10 of cash for each share of Boston Private they own. If you are a Boston Private shareholder, click here to learn more about your rights and options.MDC Partners Inc. (NASDAQ: MDCA) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its merger with Stagwell Med... |
PRVL Price Returns
| 1-mo | N/A |
| 3-mo | N/A |
| 6-mo | N/A |
| 1-year | N/A |
| 3-year | 132.56% |
| 5-year | N/A |
| YTD | N/A |
| 2022 | N/A |
| 2021 | 0.00% |
| 2020 | 45.74% |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...